Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
2 Feb, 2021 | 01:29h | UTC
Commentary on Twitter
The SARS-CoV-2 vaccine produced by Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show https://t.co/lhsB2UzD08
— The BMJ (@bmj_latest) February 1, 2021